ATI RN
ATI Pharmacology Proctored
1. A drug ending in the suffix (pril) is considered a ______.
- A. H
- B. ACE inhibitor
- C. Antifungal
- D. Beta agonist
Correct answer: B
Rationale: Drugs with names ending in -pril are classified as angiotensin-converting enzyme (ACE) inhibitors. These medications are commonly used to manage conditions like high blood pressure, heart failure, and diabetic kidney disease by blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation and decreased blood pressure.
2. What is the therapeutic classification of Furosemide?
- A. Antidiuretics
- B. Diuretics
- C. Anticonvulsants
- D. Antidotes
Correct answer: B
Rationale: Furosemide is classified therapeutically as a diuretic. Diuretics are medications used to promote diuresis, which helps the body get rid of excess salt and water. Furosemide is commonly prescribed to treat conditions such as fluid retention and swelling (edema) associated with congestive heart failure, liver disease, or kidney disorders. Choice A, Antidiuretics, is incorrect as Furosemide acts as a diuretic, promoting the production of urine. Choice C, Anticonvulsants, is also incorrect as Furosemide is not used to treat seizures. Choice D, Antidotes, is incorrect as Furosemide is not an antidote but rather a medication used to treat conditions related to fluid retention.
3. A client has a new prescription for Folic Acid. Which of the following instructions should the nurse include?
- A. Take the medication with food.
- B. Expect a metallic taste in your mouth.
- C. Increase your intake of green, leafy vegetables.
- D. Avoid citrus fruits.
Correct answer: C
Rationale: The correct answer is C: 'Increase your intake of green, leafy vegetables.' Folic acid is naturally found in green, leafy vegetables. By increasing the intake of these vegetables, the client can supplement their folic acid levels. This dietary adjustment supports the client in meeting the prescription requirements and enhances the overall health benefits of folic acid. Choices A, B, and D are incorrect because they do not directly relate to increasing folic acid intake as required by the prescription.
4. A healthcare provider is reviewing a client's medical history and notes that the client has a prescription for Digoxin. Which of the following findings is a manifestation of Digoxin toxicity?
- A. Elevated blood pressure
- B. Bradycardia
- C. Yellow-tinged vision
- D. Ringing in the ears
Correct answer: C
Rationale: Yellow-tinged vision, along with nausea, vomiting, and confusion, are common manifestations of Digoxin toxicity. Visual disturbances are important to recognize as they can indicate the need for immediate medical attention and potential adjustment of Digoxin therapy to prevent serious complications. Elevated blood pressure is not typically associated with Digoxin toxicity; instead, hypotension may occur. Bradycardia is a common therapeutic effect of Digoxin rather than a sign of toxicity. Ringing in the ears, or tinnitus, is also a potential side effect of Digoxin but is less specific to toxicity compared to yellow-tinged vision.
5. A healthcare professional is preparing to administer furosemide 80 mg PO daily. The available furosemide oral solution is 10 mg/1 mL. How many mL should the healthcare professional administer?
- A. 8 mL
- B. 10 mL
- C. 6 mL
- D. 12 mL
Correct answer: A
Rationale: To determine the volume to administer, divide the desired dose by the available concentration. In this case, 80 mg divided by 10 mg/mL equals 8 mL. Therefore, the healthcare professional should administer 8 mL of furosemide oral solution. Choice B, 10 mL, is incorrect as it does not reflect the accurate calculation. Choices C and D, 6 mL and 12 mL respectively, are also incorrect as they do not match the correct calculation based on the provided concentration and dose.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access